Management of Clinical Stage I Nonseminomatous Germ Cell Testicular Tumors: A 25-year Single-center Experience

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F17%3A10366223" target="_blank" >RIV/00216208:11110/17:10366223 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.clgc.2017.05.023" target="_blank" >http://dx.doi.org/10.1016/j.clgc.2017.05.023</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.clgc.2017.05.023" target="_blank" >10.1016/j.clgc.2017.05.023</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Management of Clinical Stage I Nonseminomatous Germ Cell Testicular Tumors: A 25-year Single-center Experience

Popis výsledku v původním jazyce

Efforts to identify patients at high risk of disease progression led to a search for risk factors in clinical stage I-nonseminomatous germ cell testicular tumors. This study analysed a 25 year single-center experience with risk-adapted therapeutic approacheseactive surveillance versus adjuvant chemotherapy. According to the results of this study, policy of active surveillance is recommended only in low-risk patients. Background: Surveillance after orchiectomy alone has become popular in the management of clinical stage I non-seminomatous germ cell testicular tumors (CSI NSGCTT). Efforts to identify patients at high risk of disease progression led to a search for risk factors in CSI NSGCTT. The aim of this study was to analyze a 25-year single-center experience with risk-adapted therapeutic approaches-active surveillance (AS) versus adjuvant chemotherapy (ACT). Patients and Methods: From January 1992 to January 2017, a total of 485 patients with CSI NSGCTT were stratified into the AS group (low-risk patients) and the ACT group (high-risk patients). Differences between relapse rates and overall survival rates in these groups were statistically analyzed. Results: In the AS group, relapse occurred in 52 (17.3%) of 301 patients with a median follow-up of 7.2 months (range, 2-86 months). Six (2.0%) patients of this group died, with a median follow-up of 34.3 months (range, 11-102 months). In the ACT group, relapse occurred in 2 (1.1%) of 184 patients with a median follow-up of 56.2 months (range, 42-70 months). One (0.54%) patient died at 139.4 months following orchiectomy. The relapse rate for the AS group was 16.7 times higher than that for the ACT group. The groups did not differ in overall survival. The 3-year overall survival of all patients with CSI NSGCTT was 99.1% (95% confidence interval, 97.7%-99.7%). Three of a total of 7 deaths occurred thereafter. Conclusions: The policy of AS is recommended only in patients with low-risk CSI NSGCTT.

Název v anglickém jazyce

Management of Clinical Stage I Nonseminomatous Germ Cell Testicular Tumors: A 25-year Single-center Experience

Popis výsledku anglicky

Efforts to identify patients at high risk of disease progression led to a search for risk factors in clinical stage I-nonseminomatous germ cell testicular tumors. This study analysed a 25 year single-center experience with risk-adapted therapeutic approacheseactive surveillance versus adjuvant chemotherapy. According to the results of this study, policy of active surveillance is recommended only in low-risk patients. Background: Surveillance after orchiectomy alone has become popular in the management of clinical stage I non-seminomatous germ cell testicular tumors (CSI NSGCTT). Efforts to identify patients at high risk of disease progression led to a search for risk factors in CSI NSGCTT. The aim of this study was to analyze a 25-year single-center experience with risk-adapted therapeutic approaches-active surveillance (AS) versus adjuvant chemotherapy (ACT). Patients and Methods: From January 1992 to January 2017, a total of 485 patients with CSI NSGCTT were stratified into the AS group (low-risk patients) and the ACT group (high-risk patients). Differences between relapse rates and overall survival rates in these groups were statistically analyzed. Results: In the AS group, relapse occurred in 52 (17.3%) of 301 patients with a median follow-up of 7.2 months (range, 2-86 months). Six (2.0%) patients of this group died, with a median follow-up of 34.3 months (range, 11-102 months). In the ACT group, relapse occurred in 2 (1.1%) of 184 patients with a median follow-up of 56.2 months (range, 42-70 months). One (0.54%) patient died at 139.4 months following orchiectomy. The relapse rate for the AS group was 16.7 times higher than that for the ACT group. The groups did not differ in overall survival. The 3-year overall survival of all patients with CSI NSGCTT was 99.1% (95% confidence interval, 97.7%-99.7%). Three of a total of 7 deaths occurred thereafter. Conclusions: The policy of AS is recommended only in patients with low-risk CSI NSGCTT.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Clinical Genitourinary Cancer

ISSN

1558-7673

e-ISSN

—

Svazek periodika

15

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

5

Strana od-do

"E1015"-"E1019"

Kód UT WoS článku

000417112200013

EID výsledku v databázi Scopus

2-s2.0-85021426206